FDA Approved Generic Lanreotide Injection
The generic version of Somatuline Depot offers an alternative for providers treating acromegaly and neuroendocrine tumors.
Updated on Sept. 18, 2026 in Healthcare
Live Poll
Do you believe the introduction of generic versions of specialized drugs improves patient access to care?
The FDA has approved a generic 120-milligram version of the injectable drug lanreotide, manufactured by Amneal Pharmaceuticals. This treatment addresses acromegaly, gastro-enteropancreatic neuroendocrine tumors, and carcinoid syndrome.
Why it matters
The approval introduces competition into a market previously served by Somatuline Depot, which recorded $983 million in U.S. sales over the 12 months ending in July 2026. This entry may alter procurement costs for clinical operators managing these hormone-related conditions.
The generic lanreotide injection enters a market where the reference product, Somatuline Depot, generated $983 million in U.S. sales for the 12 months ending in July 2026. The approval covers the 120-milligram dosage strength.
The players
Amneal Pharmaceuticals
A manufacturer specializing in generic and specialty pharmaceutical products.
Ipsen Pharma
The pharmaceutical company that holds the trademark for the branded drug Somatuline.
Food and Drug Administration
The federal regulatory agency responsible for overseeing the safety and efficacy of medical products in the United States.
The details
The FDA designated the product as a generic version of Ipsen Pharma's Somatuline Depot, allowing it to compete as a treatment for acromegaly and specific neuroendocrine tumors. The drug functions by controlling hormone levels in patients, providing a therapeutic equivalent to the established branded medication. Amneal Pharmaceuticals plans to launch the product immediately following the agency approval.
Timeline
September 18, 2026: FDA approved the generic version of lanreotide.
July 2026: The reference drug Somatuline Depot concluded a 12-month period with $983 million in U.S. sales.
Market Landscape
This approval follows the regulatory framework established by the Hatch-Waxman Act, which governs the introduction of generic competitors to branded pharmaceuticals. It marks a shift in the supply landscape for treatments previously dominated by Ipsen Pharma.
Clinical operators and pharmacy procurement managers should prepare to evaluate the generic lanreotide for their formularies. Monitor billing and supply chain changes as the introduction of this alternative may impact future drug spend.
The takeaway
The arrival of generic lanreotide represents a significant opportunity to adjust procurement costs for hormone therapy. Managers should track the entry price of this generic against the branded Somatuline Depot to identify potential savings for their clinical operations.
Further reading
For more on industry shifts, visit the Healthcare section.
Live Poll
Do you believe the introduction of generic versions of specialized drugs improves patient access to care?
